10x Genomics, Inc. (TXG) financials

10x Genomics, Inc. (TXG) revenue, EBIT and EBITDA, earnings per share, free cash flow, margins, debt and shareholders equity — annual and quarterly history, charted from SEC filings. No account needed.

In fiscal 2025, 10x Genomics, Inc. reported revenue of $643M, up 5.2% year over year, net income of -$44M, diluted EPS of -$0.35 and free cash flow of $130M.

Revenue (fiscal 2025)

$643M

Revenue growth (fiscal 2025)

5.2%

Net income (fiscal 2025)

-$44M

Diluted EPS (fiscal 2025)

-$0.35

Free cash flow (fiscal 2025)

$130M

10x Genomics, Inc. files with the U.S. Securities and Exchange Commission under CIK 0001770787, classified as Laboratory Analytical Instruments.

Explore annual and quarterly revenue, earnings, cash flow, margins, debt and equity from SEC filings.